146 related articles for article (PubMed ID: 35644778)
1. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
[TBL] [Abstract][Full Text] [Related]
2. Analysis of dose to the macula, optic disc, and lens in relation to vision toxicities - A retrospective study using COMS eye plaques.
Oare C; Sun S; Dusenbery K; Reynolds M; Koozekanani D; Gerbi B; Ferreira C
Phys Med; 2022 Sep; 101():71-78. PubMed ID: 35981450
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
Krema H; Heydarian M; Beiki-Ardakani A; Weisbrod D; Xu W; Laperriere NJ; Sahgal A
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):510-5. PubMed ID: 23507292
[TBL] [Abstract][Full Text] [Related]
6. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
[TBL] [Abstract][Full Text] [Related]
7. Ocular complications after iodine brachytherapy for large uveal melanomas.
Puusaari I; Heikkonen J; Kivelä T
Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
[TBL] [Abstract][Full Text] [Related]
8. Optic disc dose reduction in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
J Appl Clin Med Phys; 2020 Sep; 21(9):57-70. PubMed ID: 32656945
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
[TBL] [Abstract][Full Text] [Related]
10. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
11. PARAFOVEAL CAPILLARY DENSITY AFTER PLAQUE RADIOTHERAPY FOR CHOROIDAL MELANOMA: Analysis of Eyes Without Radiation Maculopathy.
Say EA; Samara WA; Khoo CT; Magrath GN; Sharma P; Ferenczy S; Shields CL
Retina; 2016 Sep; 36(9):1670-8. PubMed ID: 27232466
[TBL] [Abstract][Full Text] [Related]
12. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.
Saconn PA; Gee CJ; Greven CM; McCoy TP; Ekstrand KE; Greven KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):844-8. PubMed ID: 20171804
[TBL] [Abstract][Full Text] [Related]
13. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
Krema H; Xu W; Payne D; Vasquez LM; Pavlin CJ; Simpson R
Can J Ophthalmol; 2011 Apr; 46(2):158-63. PubMed ID: 21708084
[TBL] [Abstract][Full Text] [Related]
14. NEW ULTRA-WIDE-FIELD ANGIOGRAPHIC GRADING SCHEME FOR RADIATION RETINOPATHY AFTER IODINE-125 BRACHYTHERAPY FOR UVEAL MELANOMA.
McCannel TA; Kim E; Kamrava M; Lamb J; Caprioli J; Yang D; McCannel CA
Retina; 2018 Dec; 38(12):2415-2421. PubMed ID: 29016456
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
16. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.
Yousef YA; Finger PT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1107-12. PubMed ID: 22172910
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone acetonide for acute radiation papillopathy.
Shields CL; Demirci H; Marr BP; Mashayekhi A; Dai VV; Materin MA; Shields JA
Retina; 2006; 26(5):537-44. PubMed ID: 16770260
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
19. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
[TBL] [Abstract][Full Text] [Related]
20. Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.
Hegde JV; McCannel TA; McCannel CA; Lamb J; Wang PC; Veruttipong D; Almanzor R; Demanes DJ; Kamrava M
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1843-1850. PubMed ID: 28597076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
